Loading
England built specialist units for 13 to 24 year olds and then evaluated them nationally, which almost no health system does. The results were mixed enough that young people were asked to interpret them, and they pointed out that three years of follow-up was too short and that the study had defined specialist care by how many admissions a person had rather than how long they spent there.
The case for age-specific services is straightforward: a seventeen-year-old on a children's ward or an elderly medical ward is in the wrong place, is unlikely to meet anyone their age, and has needs around education, independence, sexuality and fertility that neither ward is set up for. In the United Kingdom, Teenage Cancer Trust has funded and run specialist units inside NHS hospitals since 1990, with specialist nurses and youth support coordinators, campaigning for age-appropriate care for 13 to 24 year olds. NICE quality standard QS55 covers ages 0 to 24 and is supported by both Teenage Cancer Trust and Teenagers and Young Adults with Cancer, and NICE's 2005 service guideline requires that care be appropriate for the child's or young person's age.
Then England did something unusual and evaluated it. BRIGHTLIGHT was "the first national evaluation of teenage and young adult (TYA) cancer services in England", covering young people aged 13 to 24 at diagnosis, comprising six interlinked studies, with young people involved in design, troubleshooting and dissemination. Its conclusions diverged in ways the professionals could not explain, so the researchers took the results back to the BRIGHTLIGHT Young Advisory Panel for interpretation. The panel made points the researchers had not: that three years of follow-up "was not long enough"; that specialist care had been defined "using number of admissions rather than duration of hospitalisation"; that the higher healthcare costs observed in those receiving care in more than one hospital "could be due to duplication of tests/scans"; and that the results did not convey the importance of the diagnostic experience, which also carried costs to young people and families. This is an unusually honest piece of health services research and it is the reason this record is graded moderate rather than strong: the services are plainly better for the people in them, and the trial-grade evidence that they change outcomes is not there.
What happened next. A policy lab brought eighteen professionals and five young people together to reconcile the evidence with NHS England's service specification for adolescent and young adult cancer, which had been drafted before the BRIGHTLIGHT results were available. It produced eight national and six local recommendations, prioritised into three: launching the service specification with clear communication, harnessing the ideas of young people, and evaluating patient outcomes and experiences through a national dashboard of network performance.
What a young person should expect to be offered. Treatment in or linked to an age-appropriate unit, a key worker, a fertility discussion before treatment starts, educational and employment support, psychological support, and an end-of-treatment summary and care plan with agreed follow-up, which is a NICE quality statement and can be asked for by name.
What comes back, and when: not a physiological question. What these services restore is the ordinary business of being that age during treatment, and the evidence that they do so is largely the testimony of the people who used them, which this record treats as evidence rather than anecdote while saying what kind it is.
Age-appropriate services aim at the non-biological determinants of outcome in this group: trial enrolment, adherence, psychological wellbeing, education and fertility decisions. Because those determinants act slowly and through many paths, a three-year observational evaluation is poorly powered to detect their effect, which is the most likely explanation for the divergence between the measured results and the experience reported by the people receiving the care.
Query for this technology: (TITLE:"Services built for teenagers and young adults, and what the national evaluation found" OR ABSTRACT:"Services built for teenagers and young adults, and what the national evaluation found") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Services built for teenagers and young adults, and what the national evaluation found, not a curated reading list.
Shares The handover from children's to adult services, where follow-up falls away, Adolescents and young adults: a group with its own cancers, its own gap and its own needs, Ewing sarcoma, Childhood cancers (all types) and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Oncofertility and fertility preservation, Testicular germ cell tumours, Ewing sarcoma, Childhood cancers (all types) and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Long-term follow-up in the United Kingdom: what a survivor is actually offered, The handover from children's to adult services, where follow-up falls away, Childhood cancers (all types), Fragmented care and guideline gaps and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Oncofertility and fertility preservation, Ewing sarcoma, Childhood cancers (all types), Osteosarcoma and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Education, work and the years that were interrupted, Childhood cancers (all types), Quality of life, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Ewing sarcoma, Childhood cancers (all types), Osteosarcoma, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Ewing sarcoma, Childhood cancers (all types), Osteosarcoma, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, paediatric, late-effects.
Shares Ewing sarcoma, Childhood cancers (all types), Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, paediatric, late-effects.